COVID-19 Serology and Immunosenescence

Study Overview
=================
Brief Summary
-----------------
This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors. This study also aims to stratify seroconversion by immunological profiles of the elderly patients residing in the EHPAD. This stratification requires the measurement of immunological marker levels already described in immunosenescence and also involved in the development of certain chronic infectious diseases more common in the elderly population. This analysis will enable the investigators to describe an immunological, clinical and biological profile representing a patient who has developed an immunity against COVID 19. It will also help the investigators to understand the different mechanisms leading to a reduced immune response after a potential administration of a vaccine. Finally, it will help describe the immune profiles of elderly residents who presented with non-severe forms of COVID-19.

Official Title
-----------------
Kinetics of COVID-19-neutralising Antibodies in Patients Residing in EHPAD / USLD: Influence of Immunosenescence

Conditions
-----------------
Covid19, Geriatric Medicine, Seroconversion, Immunosenescence

Intervention / Treatment
-----------------
* Biological: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Residents of the EHPAD/USLD St Victor of the Amiens CHU who took part in the screening campaign (RT-PCR and serology) organized by the Amiens CHU residents who signed a consent form to participate in the study Exclusion Criteria: The patient or his legal representative refused to participate in the study Heavily sedated patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: COVID-19 positive resident<br> | Biological: blood sample<br>* Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.<br>|
| Active Comparator: COVID-19 negative resident<br> | Biological: blood sample<br>* Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| titers of COVID-19 neutralising antibodies |  | day 0 | 
| titers of COVID-19 neutralising antibodies |  | at 3 months | 
| titers of COVID-19 neutralising antibodies |  | at 6 months | 
| titers of COVID-19 neutralising antibodies |  | at 9 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid19, geriatric medicine, seroconversion, immunosenescence